News & Perspective

Nov 27, 2007

Nov 27, 2007

FDA panel seeks stronger label warnings for 2 flu drugs

(CIDRAP News) – The US Food and Drug Administration's (FDA's) Pediatric Advisory Committee voted today to recommend stronger label warnings for two antiviral influenza medications—oseltamivir and zanamivir—that have been linked to reports of neuropsychiatric problems in children and teens, mainly in Japan.

Oseltamivir already carries a warning, but zanamivir currently carries no warning about reported neuropsychiatric effects.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Jun 20, 2007

Jun 20, 2007

Japanese to study behavioral effects of Tamiflu

(CIDRAP News) – The company that markets oseltamivir (Tamiflu) in Japan has announced it will launch new studies to explore whether the antiviral drug contributes to adverse psychiatric and neurologic events in teenagers.

Mar 21, 2007

Mar 21, 2007

Japan warns against Tamiflu use in teens

(CIDRAP News) – Japan's health ministry today ordered the country's importer of oseltamivir (Tamiflu) to warn doctors against prescribing the drug to teens, because of continuing concerns that psychiatric symptoms might be linked to the influenza medication, according to news services.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»


Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


  Become an underwriter»